TrialCell reports. Medicine2025

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.

Juanita Suzanne Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.